Anzeige
Mehr »
Freitag, 04.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von PMLiVE

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
09.06.Improving patients' mental health: the role of healthcare comms
09.06.The outlook for healthcare comms in 2025
06.06.Eli Lilly and Camurus enter cardiometabolic health partnership worth up to $870m
06.06.AstraZeneca's Calquence approved by EC for first-line chronic lymphocytic leukaemia use
06.06.Conferences: the value of real experience versus virtual convenience
06.06.The power of creativity in healthcare PR
05.06.Roche's Evrysdi tablets granted EC approval to treat spinal muscular atrophy
05.06.VML Health appoints Nick Bartlett as chief executive officer of EU hub
05.06.Essential agility in an era of change for medical affairs
05.06.How AI can humanise data and transform healthcare communications
04.06.Regeneron gains rights to Hansoh's GLP-1/GIP receptor agonist in deal worth $2bn
04.06.Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma
04.06.Dermaliq and DEBRA partner to advance epidermolysis bullosa drug delivery
04.06.Inizio Evoke appoints Matthew Hoelzle as chief medical officer
04.06.Building inclusive clinical trials through policy reform
04.06.Turning cold facts into compassionate conversations: the power of patient-centricity in medical education
03.06.BMS and BioNTech partner on solid tumour candidate in deal worth over $11bn
03.06.AstraZeneca's Forxiga recommended by NICE for wider chronic kidney disease use
03.06.Roche/Jazz Pharmaceuticals share positive phase 3 results for lung cancer combination therapy
03.06.Focusing on the patient voice to improve outcomes
03.06.How can we achieve the right balance of HCP engagements in medcomms?
02.06.Pfizer shares 'unprecedented' survival results for Braftovi in colorectal cancer
02.06.Sanofi to expand immunology capabilities with $9.5bn Blueprint Medicines acquisition
02.06.Eli Lilly's Omvoh recommended by NICE to treat Crohn's disease in adults
02.06.Between luck and leadership: success because of, not despite, strategy